Rasmus Offersen

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

Jesper Damsgaard Gunst, Marie H. Pahus, Lena Hagelskjær Kristensen et al. · EClinicalMedicine · 2021 · 197 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +3

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

Line K. Vibholm, Mariane Høgsbjerg Schleimann, Jesper Falkesgaard Højen et al. · Clinical Infectious Diseases · 2017 · 146 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial

Ole S. Søgaard, Nicolai Lohse, Zitta Barrella Harboe et al. · Clinical Infectious Diseases · 2010 · 112 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4⁺T Cells

Rasmus Offersen, Sara Konstantin Nissen, Thomas A. Rasmussen et al. · Journal of Virology · 2016 · 102 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Identification of Novel Genetic Variants in CVID Patients With Autoimmunity, Autoinflammation, or Malignancy

Mette Christiansen, Rasmus Offersen, Jens Magnus Bernth Jensen et al. · Frontiers in Immunology · 2020 · 42 citations · Full text

Life Sciences, Immunology, Molecular Genetics +17